摘要
目的:研究可溶性白介素受体(sol-uble interleukin- 2 receptor, SIL- 2R)及雌激素受体(estrogen receptor, ER)在甲状腺乳头状癌的表达。方法: 应用 ELISA双抗夹心法和免疫组化 SP法对 50 例甲状腺乳头状癌、20 例滤泡状癌及 10 例髓样癌进行SIL- 2R及 ER测定。结果: 甲状腺癌患者术前血清中 SIL -2R含量(118. 20±43 50)pmol/L,明显高于甲状腺结节组(50 .28±12. 28) pmol/L 及对照组(49. 25±13. 32)pmol/L;术后20- d基本降至正常;甲状腺癌血清中SIL-2R升高与甲状腺癌的病理类型无明显关系;甲状腺乳头状癌 ER阳性表达率(67 3%)显著高于滤泡状癌(40 0%)及正常组织 ( 8 0%); 原发癌 ER 阳性率(74. 2%)明显高于复发癌(20 .0%);无淋巴结转移的甲状腺乳头状癌 ER 阳性率(68. 5%)高于有颈部淋巴结转移的甲状腺乳头状癌(46 .6%)。结论:SIL- 2R和 ER对判断甲状腺良、恶性疾病和评价疗效及预后有一定临床意义。
OBJECTIVE:To study the expression of Soluble interleukin-2 receptor (SIL-2R) and Estrogen receptor(ER) in patients with thyroid carcinoma. METHODS: Expresion of ER were detected by immunohistochemistry SP method in 50 cases of thyroid papillary carcinoma and 20 cases of follicular carcinoma and 10 cases marrow shape carcinoma.RESULTS: The SIL-2R level in patients with thyroid carcinoma were (118.20±43.50) pmol/L obviously higher than thyroid node group (50.28±12.28) pmol/L and normal control group(49.2±13.32 ) pmol/L; Serum SIL-2R level in 20 day after operation was drop to normal; There was no significant difference between thyroid carcinoma and pathological; The expression positive rate of ER in papilla shape were 67.3% obviously higher than that thyroid carcinoma of follicle (40.0%) and normal control (8.0%);The expression positive rate in primary thyroid carcinoma were 74.2% significantly highter than that in cases of recurrence (20.0%); The expression positive rate in cases without lymph node metastasis were 68.5%,highter than that in cases with lymph metastasis (46.6%). CONCLUSIONS: These suggest that there is clinical significance for distinguishing thyroid benign disease from malignant,evaluating curative effect and prognosis by measuring expression SIL-2R and ER.
出处
《肿瘤防治杂志》
2005年第3期183-185,共3页
China Journal of Cancer Prevention and Treatment